INTRA-CELLULAR THERAPIES INC (ITCI)
US46116X1019 - Common Stock
Taking everything into account, ITCI scores 5 out of 10 in our fundamental rating. ITCI was compared to 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ITCI as it has an excellent financial health rating, but there are worries on the profitability. ITCI is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ITCI had negative earnings in the past year.
In the past year ITCI has reported a negative cash flow from operations.
In the past 5 years ITCI always reported negative net income.
ITCI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -19.19%, ITCI is in the better half of the industry, outperforming 63.08% of the companies in the same industry.
ITCI's Return On Equity of -23.63% is fine compared to the rest of the industry. ITCI outperforms 71.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.19% | ||
| ROE | -23.63% | ||
| ROIC | N/A |
ROA(3y)-37.04%
ROA(5y)-40.31%
ROE(3y)-43.55%
ROE(5y)-48.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ITCI's Gross Margin of 92.72% is amongst the best of the industry. ITCI outperforms 94.87% of its industry peers.
In the last couple of years the Gross Margin of ITCI has remained more or less at the same level.
ITCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ITCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ITCI has been increased compared to 1 year ago.
Compared to 5 years ago, ITCI has more shares outstanding
There is no outstanding debt for ITCI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 28.42 indicates that ITCI is not in any danger for bankruptcy at the moment.
ITCI's Altman-Z score of 28.42 is amongst the best of the industry. ITCI outperforms 94.36% of its industry peers.
ITCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 28.42 |
ROIC/WACCN/A
WACC9.26%
2.3 Liquidity
ITCI has a Current Ratio of 5.41. This indicates that ITCI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ITCI (5.41) is better than 70.77% of its industry peers.
ITCI has a Quick Ratio of 5.31. This indicates that ITCI is financially healthy and has no problem in meeting its short term obligations.
ITCI has a better Quick ratio (5.31) than 69.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.41 | ||
| Quick Ratio | 5.31 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 46.32% over the past year.
ITCI shows a strong growth in Revenue. In the last year, the Revenue has grown by 85.46%.
ITCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 173.09% yearly.
EPS 1Y (TTM)46.32%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q33.33%
Revenue 1Y (TTM)85.46%
Revenue growth 3Y173.09%
Revenue growth 5YN/A
Revenue growth Q2Q50.28%
3.2 Future
Based on estimates for the next years, ITCI will show a very strong growth in Earnings Per Share. The EPS will grow by 55.14% on average per year.
ITCI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.68% yearly.
EPS Next Y52.33%
EPS Next 2Y69.97%
EPS Next 3Y69.51%
EPS Next 5Y55.14%
Revenue Next Year41.21%
Revenue Next 2Y40.77%
Revenue Next 3Y40.88%
Revenue Next 5Y38.68%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ITCI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ITCI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ITCI's earnings are expected to grow with 69.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.97%
EPS Next 3Y69.51%
5. Dividend
5.1 Amount
ITCI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTRA-CELLULAR THERAPIES INC
NASDAQ:ITCI (4/22/2024, 7:09:09 PM)
After market: 74.54 0 (0%)74.54
+2.17 (+3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.22B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.19% | ||
| ROE | -23.63% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.72% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.41 | ||
| Quick Ratio | 5.31 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)46.32%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y52.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)85.46%
Revenue growth 3Y173.09%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y